MNK - Mallinckrodt Public Limited Company

NYSE - NYSE Delayed Price. Currency in USD
20.63
+0.73 (+3.67%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close19.90
Open19.93
Bid20.25 x 4000
Ask0.00 x 800
Day's Range19.75 - 20.65
52 Week Range11.65 - 36.65
Volume1,315,990
Avg. Volume2,287,124
Market Cap1.719B
Beta (3Y Monthly)2.00
PE Ratio (TTM)1.04
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Markityesterday

    See what the IHS Markit Score report has to say about Mallinckrodt Plc.

    # Mallinckrodt Plc ### NYSE:MNK View full report here! ## Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high and has been increasing ## Bearish sentiment Short interest | Negative Short interest is high for MNK with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MNK. Sentiment has worsened and traders added to their bearish short positions on December 24. ## Money flow ETF/Index ownership | Negative ETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding MNK totaled $1.36 billion. Additionally, the rate of outflows appears to be accelerating. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GuruFocus.com4 days ago

    5 Health Care Stocks in Gurus' Portfolios

    Eli Lilly tops the list

  • Markit5 days ago

    See what the IHS Markit Score report has to say about Mallinckrodt Plc.

    # Mallinckrodt Plc ### NYSE:MNK View full report here! ## Summary * Bearish sentiment is high and has been increasing ## Bearish sentiment Short interest | Negative Short interest is high for MNK with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MNK. Sentiment has worsened and traders added to their bearish short positions on December 24. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $10.72 billion over the last one-month into ETFs that hold MNK are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • CNBC6 days ago

    House Democrats launch drug-pricing probe into a dozen major health-care companies

    AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.

  • The Mallinckrodt Spinoff Is a Short-Term Win
    GuruFocus.com6 days ago

    The Mallinckrodt Spinoff Is a Short-Term Win

    Mallinckrodt PLC (MNK) is in the middle of a major change to its business model -- pivoting from a focus on pain therapy toward a more branded drug operation. This transition began in 2016 as it sold off a nuclear imaging segment and, more recently, with the December announcement of the spinoff of its generic business. In recent years, despite an incredible amount of financial power and net worth, the market has been rocked by the ongoing opioid crisis, which has hit Mallinckrodt especially hard.

  • MNK vs. AMPH: Which Stock Should Value Investors Buy Now?
    Zacks9 days ago

    MNK vs. AMPH: Which Stock Should Value Investors Buy Now?

    MNK vs. AMPH: Which Stock Is the Better Value Option?

  • Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility
    Zacks10 days ago

    Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility

    Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.

  • Markit11 days ago

    See what the IHS Markit Score report has to say about Mallinckrodt Plc.

    # Mallinckrodt Plc ### NYSE:MNK View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high and has been increasing ## Bearish sentiment Short interest | Negative Short interest is high for MNK with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MNK. Sentiment has worsened and traders added to their bearish short positions on December 24. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding MNK is favorable, with net inflows of $19.86 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Cara (CARA) Up on IDMC's Recommendation to Continue Trial
    Zacks17 days ago

    Cara (CARA) Up on IDMC's Recommendation to Continue Trial

    Cara (CARA) gains after IDMC recommended the late-stage trial on lead drug, Korsuva, to continue without any modifications.

  • Heron Gains on Priority Review Designation for Pain Drug
    Zacks18 days ago

    Heron Gains on Priority Review Designation for Pain Drug

    Heron (HRTX) soars after the FDA accepted the company's NDA for pain drug, HTX-011, and granted Priority Review designation to the application.

  • See what the IHS Markit Score report has to say about Mallinckrodt Plc.
    Markit25 days ago

    See what the IHS Markit Score report has to say about Mallinckrodt Plc.

    Short interest is high for MNK with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MNK. Over the last month, growth of ETFs holding MNK is favorable, with net inflows of $19.42 billion.

  • Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III
    Zacks27 days ago

    Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III

    Mallinckrodt (MNK) and partner NPXe Limited enrol the first patient in the phase III study on xenon gas for inhalation (XENEX) for Post Cardiac Arrest Syndrome (PCAS).

  • Year in review: Hospital shakeups, urgent care invasion lead health care news cycle
    American City Business Journalslast month

    Year in review: Hospital shakeups, urgent care invasion lead health care news cycle

    From hospital leadership teams resigning to the influx of urgent care facilities popping up all over the St. Louis-region — these were the biggest health care stories of 2018.

  • The Wall Street Journallast month

    [$$] Federal Judge Strikes Down New York Tax on Opioid Industry

    A federal judge struck down Wednesday a New York law that aimed to collect $600 million from the pharmaceutical industry to help combat the opioid crisis, a ruling that could shape opioid legislation being weighed in other states. U.S. District Judge Katherine Polk Failla in Manhattan called the novel law an unconstitutional regulatory penalty on the makers and distributors of opioid painkillers, even as she acknowledged the validity of trying to legislate a solution to the epidemic gripping the nation. The ruling comes days before a deadline set by New York’s health department to pay the first installment of the levy.

  • See what the IHS Markit Score report has to say about Mallinckrodt Plc.
    Markitlast month

    See what the IHS Markit Score report has to say about Mallinckrodt Plc.

    This means that investors who seek to profit from falling equity prices are currently targeting MNK. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • Reuterslast month

    Judge blocks New York from enforcing opioid surcharge on companies

    A Manhattan federal judge on Wednesday blocked New York state from enforcing a recently enacted law that aimed to collect $600 million from drug manufacturers and distributors to defray the costs of combating the opioid addiction epidemic. U.S. District Judge Katherine Polk Failla ruled that while the concerns driving New York's decision to adopt the law were valid, the means by which the state would extract payments from the companies violated the U.S. Constitution. Failla said the law's prohibition on companies passing on to consumers the costs of making the payments to the state of New York violated the Constitution's "dormant" Commerce Clause, which bars states from regulating interstate commerce.

  • Is Mallinckrodt Public Limited Company (MNK) A Good Stock To Buy?
    Insider Monkeylast month

    Is Mallinckrodt Public Limited Company (MNK) A Good Stock To Buy?

    During the first half of the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by about 4 percentage points as investors worried over the possible ramifications of rising interest rates. The hedge funds and institutional investors we track typically invest more in smaller-cap stocks than an average investor (i.e. […]

  • Zackslast month

    Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA

    Mallinckrodt (MNK) receives complete response letter from the FDA related to its regulatory application seeking approval for abuse-deterrent reformulation of opioid painkiller, Roxicodone.

  • Markitlast month

    See what the IHS Markit Score report has to say about Mallinckrodt Plc.

    # Mallinckrodt Plc ### NYSE:MNK Score: Negative (18) 8 days at current score. Downgraded from Neutral on December 6th 2018 View full report here! ## Summary * This company ranked negatively compared to the Healthcare sector despite 2 positive IHS Markit Categories * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Negative Short interest is high for MNK with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MNK. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding MNK are favorable, with net inflows of $12.16 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Benzingalast month

    FDA Snubs Mallinckrodt's Abuse-Deterrent Opioid Reformulation

    Mallinckrodt's generic subsidiary SpecGx LLC said it received a CRL from the FDA pertaining to its NDA for its investigational abuse-deterrent, immediate-release reformulation of its oxycodone hydrochloride tablets. The pipeline candidate is being evaluated to manage pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. A CRL is issued to an applicant if the FDA determines that the application or abbreviated application cannot be approved in its current form.

  • Reuterslast month

    FDA declines to approve Mallinckrodt's abuse-deterrent opioid painkiller

    The treatment is a reformulated version of the company's commonly abused painkiller Roxicodone, intended to make the drug less desirable and more difficult to be abused by snorting or injecting. Mallinckrodt's shares fell 4.4 percent to $20.02 in premarket trading on Wednesday. The decision comes after an advisory panel to the FDA voted 10-7 in favor of the drug, saying it should be labeled as abuse deterrent only by the nasal route.

  • The Wall Street Journallast month

    [$$] FDA Doesn't Approve Mallinckrodt's Abuse-Deterrent Roxicodone

    PLC (MNK) on Wednesday said the U.S. Food and Drug Administration indicated it won’t approve the company’s new-drug application for the abuse-deterrent, immediate-release reformulation of the painkiller Roxicodone in its current form. The U.K.-based specialty-pharmaceutical company said its SpecGx LLC unit, which operates its specialty-generics business, received a complete response letter from the FDA that provided guidance on areas of further evaluation needed to resubmit the NDA for further review and potential approval. The agency routinely sends such letters when it determines that a drug application needs more data or research.

  • MarketWatchlast month

    Mallinckrodt shares slide 4% premarket after pain treatment approval delayed

    Mallinckrodt plc said Wednesday its SpecGx LLC subsidiary has received a Complete Response Letter from the U.S. Food and Drug Administration regarding its new drug application for Roxicodone, a treatment for pain that is severe enough to require an opioid. The letter provides guidance on areas of further evaluation needed to resubmit the NDA for further review and possible approval. The FDA routinely sends such letters when a drug application is deemed to require further data or research. Roxicodone is an abuse-deterrent, immediate-release formulation that the company is developing as part of an effort to stem the current opioid addiction crisis in the U.S., according to Mallinckrodt. "We are evaluating the FDA's letter and will request a meeting in the coming weeks to discuss it further," Matt Harbaugh, president, specialty generics, said in a statement. Shares fell 4.4% premarket on the news, but are down 7% in 2018, while the S&P 500 has fallen 1.4%.

  • Reuterslast month

    FDA declines to approve reformulated Mallinckrodt opioid

    Mallinckrodt Plc said on Wednesday the U.S. Food and Drug Administration declined to approve an abuse-deterrent version of its opioid painkiller Roxicodone. Certain parts of the company's application need further evaluation, Mallinckrodt said, citing the FDA. The treatment is a reformulated version of Mallinckrodt's commonly abused painkiller Roxicodone, intended to make the drug less desirable and more difficult to be abused by snorting or injecting.

  • Mallinckrodt (MNK) to Separate Generics & Branded Businesses
    Zackslast month

    Mallinckrodt (MNK) to Separate Generics & Branded Businesses

    Mallinckrodt (MNK) announces plans to split its generic and branded businesses into two different companies.